Last reviewed · How we verify
Continuous Apomorphine infusion
Apomorphine is a dopamine agonist that stimulates dopamine receptors in the brain to improve motor symptoms in Parkinson's disease.
Apomorphine is a dopamine agonist that stimulates dopamine receptors in the brain to improve motor symptoms in Parkinson's disease. Used for Advanced Parkinson's disease with motor fluctuations.
At a glance
| Generic name | Continuous Apomorphine infusion |
|---|---|
| Sponsor | Rennes University Hospital |
| Drug class | Dopamine agonist |
| Target | Dopamine receptors (D2, D3) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Apomorphine acts as a non-selective dopamine receptor agonist, primarily binding to D2 and D3 dopamine receptors. In Parkinson's disease, continuous subcutaneous or intravenous infusion maintains steady dopamine receptor stimulation, reducing motor fluctuations and improving motor control compared to intermittent dosing. This approach bypasses the need for intact dopaminergic neurons and provides more stable dopaminergic signaling.
Approved indications
- Advanced Parkinson's disease with motor fluctuations
Common side effects
- Nausea
- Injection site reactions
- Dyskinesias
- Hypotension
- Hallucinations
Key clinical trials
- Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:
- Infusion of Apomorphine: Long-term Safety Study (PHASE3)
- Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease (PHASE4)
- Apomorphine in Severe Brain-injured Patients (PHASE2, PHASE3)
- Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease
- Development of a Proactive Health Care Pathway When Initiating Continuous Subcutaneous Apomorphine Infusion in Patients With Parkinson Disease : Impact on Their Autonomy (AUTAP) (NA)
- Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease (PHASE3)
- Treating Severe Brain-injured Patients With Apomorphine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continuous Apomorphine infusion CI brief — competitive landscape report
- Continuous Apomorphine infusion updates RSS · CI watch RSS
- Rennes University Hospital portfolio CI